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Membrane permeabilityAntibiotics acting on bacterial membranes are receiving increasing attention because of widespread
resistance to agents acting on other targets and of potentially improved bactericidal effects. Oritavancin is a
amphiphilic derivative of vancomycin showing fast and extensive killing activities against multi-resistant
(including vancomycin insusceptible) Gram-positive organisms with no marked toxicity towards eukaryotic
cells. We have undertaken to characterize the interactions of oritavancin with phospholipid bilayers, using
liposomes (LUV) and supported bilayers made of cardiolipin (CL) or phosphatidylglycerol (POPG) and
phosphatidylethanolamine (POPE), all abundant in Gram-positive organisms. Changes in membrane
permeability were followed by the release of calcein entrapped in liposomes at self-quenching
concentrations, and changes in nanoscale lipid organization examined by Atomic Force Microscopy (AFM).
Oritavancin caused a fast (b5 min) and complete (N95%) release of calcein from CL:POPE liposomes, and a
slower but still substantial (50% in 60 min) release from POPG:POPE liposomes, which was (i) concentration-
dependent (0–600 nM; [microbiologically meaningful concentrations]); (ii) enhanced by an increase in
POPG:POPE ratio, and decreased when replacing POPG by DPPG. AFM of CL:POPE supported bilayers showed
that oritavancin (84 nM) caused a remodeling of the lipid domains combined with a redisposition of the drug
and degradation of the borders. In all the above studies, vancomycin was without a signiﬁcant effect at
5.5 μM. Electrostatic interactions, together with lipid curvature, lipid polymorphism as well of ﬂuidity play a
critical role for the permeabilization of lipid bilayer and changes in lipid organization induced by oritavancin.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Biological membranes act as semi-permeable barriers to allow the
inside environment of cells or organelles to differ from that outside
medium, and mediate cell communications and interactions. In Gram-
positive bacteria, thepericellularmembrane is surroundedbya thick cell
wall of peptidoglycan that confers mechanical resistance to external
osmotic and other physical stress. Both the pericellular membrane and
the cell wall of peptidoglycan are essential for cell survival, and,
therefore, are privileged targets in antibacterial chemotherapy. Anti-
biotics that act on the membrane of Gram-positive organisms include
daptomycin and nisin. Daptomycin is a lipopeptide approved for clinical
use which, after complexation with Ca+, forms an oligomeric assembly
exerting a detergent-like effect towards bilayers with a high content in
negatively-chargedheadgroups, such as those found in bacteria, causing
leakage of cytosolic contents [1]. Nisin kills bacteria by forming a pore32 2 764 73 73.
(M.-P. Mingeot-Leclercq).
ll rights reserved.complex together with lipid II [2]. Antibiotics acting on the formation of
the bacterial cell wall include the β-lactams, which act primarily by
inhibition of the transpeptidases (or penicillin-binding proteins and
impair the reticulation of the peptidoglycan [3] and the glycopeptides
(vancomycin, teicoplanin) that act by binding to the D-Ala–D-Ala
sequence of the pentapeptide of lipid II, thereby preventing the
transpeptidation and transglycosylation reactions in the late stages of
peptidoglycan synthesis [4]. Both approaches, however, have their
limitations, with the most striking examples of the emergence of
resistance of a major medical importance being shown by Staphylococ-
cus aureus. This pathogenhas indeed acquiredmechanisms of resistance
to β-lactams (under the form of the so-called methicillin-resistant
organisms that produce a transpeptidase [PBP 2a] with decreased
afﬁnity for β-lactams [5], to glycopeptides (with the emergence of the
so-called glycopeptide-intermediate S. aureus characterized by a
thickened cell wall, and also of fully resistant organisms in which the
terminal D-Ala is replaced by Ser or a lactate [6], and to daptomycin (by
alteration of the biosynthetic pathway of phosphatidylglycerol and/or
by acquisition of a thickened cell wall (see [7] for review).
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a new class of derivatives called collectively lipoglycopeptides which
show improved activity against such multi-resistant strains (see [8]
for review). Among them, oritavancin (LY333328) is the most active
against vancomycin-resistant organisms [7]. Compared to vancomy-
cin, oritavancin possesses a 4-(4-chlorophenyl)-phenylmethyl side
chain [9,10], synthetically added to the natural product precursor,
chloroeremomycin, which differs from vancomycin by the presence of
a 4-epi-vancosamine sugar (Fig. 1). Oritavancin, as well as another
lipoglycopeptide, telavancin, is considerably more rapidly bactericidal
than vancomycin, suggesting a novelmode of action that could involve
membrane destabilization [11–13]. This mechanism ought to be
speciﬁc of bacteria since both compounds are devoid of marked
toxicities towards eukaryotic cells and have been successfully brought
to clinical applications in humans [7,11].
Because interactions of lipoglycopeptides in general, and of orita-
vancin in particular, with model membranes is still largely unexplored,
we attempted to further characterize them using a multidisciplinary
approach but taking care of using conditions that mimicked those under
which the drug exerts its antibacterial effects. As maintenance of a
permeability barrier is the central property of biological membranes, we
ﬁrst compared the ability of oritavancin and vancomycin to permeabilize
lipid bilayers. The results were correlated with real-time observations of
the interactions of both molecules with lipids at the nanoscale level
using Atomic Force Microscopy (AFM) [14]. Since the bacterial
membrane is rich in acidic phospholipids [15], we used liposomes and
supported bilayers made of cardiolipin (CL) or phosphatidylglycerol
(PG) and phosphatidylethanolamine (PE). PG is the predominant
phospholipid in the membranes of S. aureus [16], and cardiolipin is
also found at high levels in these bacteria [17] as well several other
Gram-positive organisms [15,18]. While being more abundant in Gram-
negative bacteria, PE is nevertheless present in S. aureus [19,20].
2. Materials and methods
2.1. Materials
Beef heart cardiolipin (CL; Disodium Salt; purity N99%), and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), 1-palmi-Fig. 1. Structural formulae of vancomycin and oritavancin. Key differences are (i) the chloro
hydrophobic character to the molecule, and (ii) the amino group present in the additional e
calculated log P and log D (at pH 7) of vancomycin are –1.44 and –4.70, and those of oritavtoyl-2-palmitoyl-sn-glycero-3-phosphoglycerol (DPPG), 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoethanol-amine (POPE) were purchased from
Avanti Polar Lipids (Alabaster, AL) and used without further puriﬁca-
tion. Calcein was purchased from Sigma-Aldrich (St. Louis, MO) and
was puriﬁed as described previously [21]. Brieﬂy, calcein was
dissolved in 6 N NaOH and subjected to size-exclusion chromato-
graphy through a SephadexR LH-20 column. The ﬁnal concentration of
calcein solution in 20 mM Tris–HCl was 73 mM with an osmolarity of
434 mOsm/kg (measured by the freezing point technique, using a
model 3C2 Advanced Cryomatic Osmometer [Advanced Instruments,
Needham Heights, MA]). Oritavancin diphosphate powder was
supplied by Targanta Therapeutics, Cambridge, MA, as microbiological
standard for in vitro investigations. It was dissolved in water contain-
ing 0.002% polysorbate-80 (vol:vol). Vancomycin was obtained from
GlaxoSmithKline s.a., Genval, Belgium as the product registered for
parenteral use in humans and complying with the provisions of the
European Pharmacopeia.
2.2. Large unilamellar vesicle preparation
Lipids were dissolved in CHCl3:CH3OH (2:1, v/v) and mixed to
obtain the desired composition in a round ﬂask. The solvent was
evaporated using a Rotavapor system (model R-210, Buchi Labortech-
nik AG, Flawil, Switzwerland). Dried ﬁlms were maintained under
reduced pressure overnight and thereafter hydratedwith 20mMTris–
HCl,150mMNaCl, 20mMCaCl2 2H20, pH 7.4 for AFM studies andwith
the puriﬁed calcein for permeability experiments. Large Unilamellar
Vesicles (LUV) were obtained after 5 cycles of freeze/thawing and 10
cycles of extrusion in a 10 mL Thermobarrel Extruder (Lipex
Biomembranes, Vancouver, Canada) under a nitrogen pressure of 10
bars through two polycarbonate ﬁlters of 100 nm or 400 nm pore size
for permeability and AFM studies, respectively (Nucleopore, Costar
Corporation, Badhoevedorp, The Netherlands). Non-entrapped calcein
was removed using minicolumn centrifugation [21]. The size and
polydispersity of liposome suspensions (Table 1) were monitored by
quasi-elastic light scattering with a Zetasizer Nano SZ (Malvern
Instruments, Worcestershire, UK). Lipid concentration on the liposo-
mal suspensions was measured by phosphorous quantiﬁcation [22].-biphenyl methylene moiety (block arrow; absent in vancomycin) that confers a more
pi-vancosamine moiety (thin arrow) that contributes to its amphipathic character. The
ancin 4.10 and –3.43.
Table 1
Diameter and polydispersity index of liposomes used for permeability studies
(measured by quasi-elastic light scattering).
Composition Diameter (nm) Polydispersity index
POPC:POPE (4:8, mol:mol) 114.1 0.172
POPG:POPE: (4:8, mol:mol) 109.9 0.110
CL:POPE: (2:8, mol:mol) 127.6 0.145
DPPG:POPE: (4:8, mol:mol) 103.1 0.079
Fig. 2. Release of calcein from liposomes (5 μM phospholipids) made of CL:POPE (2:8
molar ratio; upright triangles) or POPG:POPE (4:8 molar ratio; upside down triangles)
upon exposure at 37°C to 600 nMoritavancin (ORI; ﬁlled symbols) or vancomycin (VAN;
open symbols). (A) 0–60 min exposure time; (B) 0–200 s exposure time (CL:POPE
liposomes only). The ordinate shows the percentage of calcein released compared to
what was observed after addition of 2% Triton X-100. Each value is the mean of three
independent experimental determinations ±SEM (when not visible, the bars are
smaller than the symbols). For oritavancin, the graph shows the functions obtained by
ﬁtting a one phase exponential association function to the data by non-linear regression.
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The liposome total phospholipid concentration was adjusted to a
ﬁnal concentration of 5 μM with isoosmotic buffer (20 mM Tris–HCl,
200 mMNaCl, pH 7.4). After overnight storage at 4 °C, liposomes were
exposed to the drug under study at 37 °C at the desired concentration
and for the suitable timewith continuous stirring and protection from
light. Leakage of entrapped calcein was monitored by the increase in
ﬂuorescence of the samples, resulting from the dilution and release of
self-quenching of this tracer [23]. All ﬂuorescence determinations
were performed on an LS 55 ﬂuorescence spectrophotometer (Perkin-
Elmer Ltd., Beaconsﬁeld, UK) using λexc and λem of 476 nm and
512 nm, respectively and slits ﬁxed at 3 nm. The percentage of calcein
released under the inﬂuence of drug was deﬁned as [(Ft−Fcontr)/
(Ftot−Fcontr)]×100, where Ft is the ﬂuorescence signal measured at
time t in the presence of drug, Fcontr is the ﬂuorescence signal
measured at the same time in the absence of drug, and Ftot is the total
ﬂuorescence signal obtained after complete disruption of liposomes
by Triton X-100 at a ﬁnal concentration of 2% (checked by quasi-elastic
light spectroscopy) [21].
2.4. Atomic force microscopy
Before each experiment, the contact mode cell was extensively
washed with ethanol and water. Mica squares (0.25 cm2) were glued
onto a steel disc, cleaned carefully with water before use and cleaved
to obtain a ﬂat and uniform surface. Immediately, an aliquot of 50 μL of
vesicles (CL:POPE [2:8] or POPE only; adjusted to 250 μM in 20 mM
Tris–HCl, 150 mM NaCl, 20 mM CaCl2 2H20, pH 7.4), was deposited on
the mica surface and incubated for 1 h at room temperature. The
sample was thereafter washed with buffer (20 mM Tris–HCl, 150 mM
NaCl, pH 7.4) to eliminate non-adsorbed vesicles. AFM contact mode
images in liquid were obtained using a Nanoscope IV Multimode AFM
(Veeco Metrology Group, Santa Barbara, CA) with triangular Si3N4
cantilevers (Microlevers, Veeco Metrology Group, Santa Barbara, CA.)
with a nominal spring constant of 0.01 N m−1. The instrument was
equipped with a “J” scanner (120 μm). To minimize the applied force
on the sample the set point was continuously adjusted during
imaging. Images were acquired at 90° scan angle with a scan rate of
2 Hz. All images were processed using the Veeco software.
3. Results
3.1. Membrane permeability
The effect of oritavancin and vancomycin at a ﬁxed concentration
(600 nM) on the permeability of liposomes made of CL:POPE (2:8) or
POPG:POPE (4:8) (so as to obtain the same amount of negative
charges) is shown in Fig. 2A. Oritavancin caused a release of calcein
that was almost immediate (less than 5 min) and complete when
added to CL:POPE liposomes. The release of calcein was slower but
eventually reached about 50% within 60 min when oritavancin was
added to POPG:POPE liposomes (maintaining oritavancin in contact
with these liposomes for up to 8 h caused about 60% calcein release).
Vancomycin was almost without effect on both CL:POPE and POPG:
POPE liposomes. To obtain more information about the true rate of
release of calcein from CL:POPE liposomes upon exposure tooritavancin, experiments were repeated using shorter periods of
contact (0–200 s). Results presented in Fig. 2B show that 50% calcein
release was obtained within about 50 s. Vancomycin was without
constant effect under these conditions.
In a second series of experiments, we examined the effect of
oritavancin concentration on the permeabilization of CL:POPE and
POPG:POPE vesicles. The concentration range chosen (0–600 nM)was
meant to attain the values reported as causing bacterial death of S.
aureus in vitro (0.12–1 mg/L [66–550 nM], depending upon assay
conditions [24,25]. The results, as seen after 8 h of contact (to ensure
maximal effects) are presented in Fig. 3. Oritavancin caused a
concentration-dependent release of calcein that reached a value
close to 98% at 600 nM when tested against CL:POPE liposomes, and
60% for POPG:POPE liposomes. Vancomycin was without signiﬁcant
effect over the same range of concentrations (data not shown).
The experiments reported so far did not address the question as to
whether the permeabilization effect seenwith oritavancinwas related
to a bilayer charge per se or to hydrophobic interactions between this
lipoglycopeptide and membranes. We, therefore, used POPG:POPE
and POPC:POPE vesicles and examined the effect of changing the ratio
between POPG and POPE and between POPC and POPE on the ability of
oritavancin to cause calcein release. The results presented in Fig. 4
show that an increase of the POPG to POPE ratio from 0.5 to 0.75 was
associated with an increase of calcein release, above which only a
Fig. 4. Release of calcein from liposomes (5 μM phospholipids) made of POPG:POPE
(triangles) or POPC:POPE (squares) of variable composition (see abscissa) upon
exposure at 37 °C and for 8 h to 600 nM (1.08mg/L) oritavancin. The ordinate shows the
percentage of calcein released compared to what was observed after addition of 2%
Triton X-100. Each value is themean of three independent experimental determinations
±SEM (when not visible, the bars are smaller than the symbols).
Fig. 3. Release of calcein from liposomes (5 μM phospholipids) made of CL:POPE (2:8
molar ratio; upright triangles) or POPG:POPE (4:8 molar ratio; upside down
triangles) upon exposure at 37 °C and for 8 h to increasing concentrations of
oritavancin (0–600 nM; 0–1.08 mg/L). The ordinate shows the percentage of calcein
released compared to what was observed after addition of 2% Triton X-100. Each
value is the mean of three independent experimental determinations ±SEM (when
not visible, the bars are smaller than the symbols).
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calcein, which was substantial when using liposomes with a low
POPC:POPE ratio (0.5) was decreased when the POPC:POPE ratio was
increased to 0.75 or more. The inﬂuence of the nature of the fatty acid
chain was also investigated by replacing POPG by DPPG in liposomes
while leaving the ratio PG:PE identical (4:8). This caused a drastic
reduction of the permeabilization effect of oritavancin that dropped
from 60% to 24% (measured after 8 h of contact with 600 nM
oritavancin).
3.2. Atomic force microscopy
To go further in the study of the interaction of oritavancin and lipid
bilayers and especially to characterize at the nanoscale, the effect of
this antibiotic on membrane organization, we prepared supported
lipid bilayers made of POPE only, or of CL:POPE (2:8). The latter
composition has been selected in view to the larger permeabilizing
effect induced by oritavancin on CL:POPE (2:8) as compared to POPG:
POPE (4:8). Supported lipid bilayers made of POPG:POPEwere already
studied by AFM for some of us [26] showing no lipid separation
between POPE and POPG. Supported bilayers of POPE and CL:POPE
were prepared by fusion of unilamellar vesicles on mica, and their
organization was imaged by AFM. Preliminary experiments assessed
the stability of POPE and CL:POPE bilayers during consecutive
scanning in buffer. Successive images of the same bilayer location
were recorded but this did not cause any signiﬁcant change of the
surface morphology, indicating that the bilayer was stable in these
conditions for at least 3 h.
3.2.1. POPE bilayers
Fig. 5A shows a typical topographic image of a POPE bilayer
supported on mica recorded in buffer solution where the darkest
region is the mica surface while the brightest region is the surface of
the supported planar bilayer. The step height with respect to the mica
surface was 5.24 nm (n=50), with a roughness (Ra) mean value of
0.07 nm (n=25). Fig. 5B shows a typical image of the same bilayer
after 1 h exposure to vancomycin (5.5 μM [8 mg/L]), a concentration
resulting in a bactericidal effect towards S. aureus in vitro [27,28]. The
drug induced an erosion in the unprotected edges, border and holes, of
the supported planar bilayer, but did not substantially change its
thickness, the step height being 4.90 nm (n=50) with a roughness of
0.12 nm (n=25). When the experiment was performed in the
presence of oritavancin (84 nM [0.15 mg/L], a concentration at which
oritavancin becomes bactericidal in vitro [25], the drug induced an
erosion of the bilayer together with a decrease of the height down to4.00 nm (Fig. 5D) vs. 4.80 nm [n=50] for control (Fig. 5C) without
change in roughness (0.09 nm [n=25]). These results suggest,
therefore, that vancomycin had no major effect on the supported
planar bilayer of pure POPE whereas oritavancin induced a slight
erosion and thinning of the bilayer (Table 2).
3.2.2. CL:POPE (2:8) bilayers
In control supported bilayers, two laterally segregated domains
were observed. The step height between the uncovered mica, and the
underlying domain was 4.55 nm (n=50) with a Ra value of 0.17 nm
(n=25) (Fig. 6A). Several smaller domains were seen which were
1.03 nm (n=50) taller than the underlying domain with a mean Ra
value of 0.09 nm (n=25). These domains were clearly seen in the
cross section supported below as a protruding planar structure on the
more extended domain.
After 1 h of contact with vancomycin (5.5 μM [8 mg/L]), the
frontiers of the more extended lipid domain were eroded (Fig. 6B).
From section analysis, the more extended domain presented a height
of 3.79 nm (n=50) from the mica surface with a mean Ra value of
0.15 nm (n=25). In parallel, reorganisation and/or disappearance of
several small lipid domains was observed with solubilisation and
afterwards spreading of the material on the mica surface. Moreover,
new domains appeared which were 0.75 nm higher than the
underlying domain with a mean Ra value of 0.07 nm (n=25).
When the supported bilayers were exposed to oritavancin to a ﬁnal
concentration of 84 nM (0.15 mg/L) for 1 h, a completely different
effect was seen compared to vancomycin. While the control supported
bilayers (Fig. 6C) showed two segregated domains of 4.57 nm and
5.26 nm heights and 0.08 nm and 0.14 nm roughness, respectively,
oritavancin (Fig. 6D) caused a remodelling of the lipid domain
combined with a redisposition of the drug as well as a degradation of
the unprotected borders of the supported bilayer. Thus, oritavancin
induced a decrease of the height from 4.57 nm to 4.10 nm (n=50)
with a roughness of 0.15 nm. This underlying domain was covered by
two other domains. The ﬁrst onewas located at 0.48 nm (n=50) with
a roughness of 0.13 nmwhereas the second one, more heterogeneous,
ranged from 0.51 to 1.40 nm (n=25).
4. Discussion
The bacterial envelope has long been recognized as a critical target
for antibiotics, with β-lactams and glycopeptides—both directed
against the peptidoglycan—being the most widely used today in
clinical practice to ﬁght Gram-positive bacteria and S. aureus in
particular. In contrast, antibiotics acting on the lipidmembrane part of
Fig. 5. Nanoscale membrane activity of vancomycin (top) or oritavancin (bottom) on POPE supported bilayer. AFM height images (5 μm×5 μm; z-scale: 20 nm) of POPE supported
planar bilayer recorded prior (0 min) (A; C) or after exposure for 1 h to vancomycin (5.5 μM [8 mg/L]) (B) or oritavancin (84 nM [0.15 mg/L]) (D). Vertical cross-sections were taken
along the position indicated by the continuous line. Upper domain and mica are indicated by black and white stars, respectively.
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human medicines, mainly because of lack of speciﬁcity resulting in a
globally less favorable toxicological proﬁle. The emergence of wide-
spread resistance to β-lactams and the slow but inescapable loss of
potency of glycopeptides has, however, directed again the attention to
membrane-acting antibiotics, as these may potentially offer novel
modes of action coupled with powerful antibacterial activities [7].
Among these, lipoglycopeptides attracted increasing attention since
these have now been successfully developed clinically [29,30] and are
being considered for approval for the treatment of multi-resistant
Gram-positive organisms.
For lipoglycopeptides, differences in activities relative to vanco-
mycin do not relate to the aglycone part of these molecules, i.e. in the
D-Ala–D-Ala binding sites, since these are similar with afﬁnitiesessentially identical among all of them [31]. However, the presence of
a lipophilic tail confers the ability to lipoglycopeptides to interact with
membranes. This has been shown for telavancin, a drug with an
overall structure and antibacterial properties similar to those of
oritavancin, for which 25% only of the antibiotic is recovered in the
peptidoglycan while 75% remains associated the protoplast upon
separation of these two constituents of the bacterial envelope (vs.
N90% bound to the peptidoglycan and b10% to the protoplasts for
vancomycin) [12]. The novel mode of action proposed involves
dissipation of membrane potential and membrane permeabilization
[13], and has been related to loss of membrane integrity favored by
interaction of the drug with lipid II (the molecule that carries the D-
Ala–D-Ala terminated pentapeptide from the cytosolic to the extra-
cellular face of the bacterial membrane). Similarly, ongoing studies
Table 2
Height and roughness values in supported phospholipid bilayers of POPE (top) and CL:POPE (2:8; mol:mol) (bottom).
Height±SD (nm) Roughness (nm)
Vancomycin Before 5.24±0.19 0.07
After 4.90±0.20 0.12
Oritavancin Before 4.80±0.20 0.09
After 4.00±0.15 0.09
Domain height±SD (nm) Domain roughness (nm)
Low Intermediate High Low Intermediate High
Vancomycin Before – 4.55±0.20 5.58±0.16 – 0.17 0.09
After – 3.79±0.30 4.54±0.11 – 0.15 0.07
Oritavancin Before 4.57±0.15 5.26±0.20 – 0.08 0.14
After 4.10 ± 0.30 4.58±0.07 4.61–5.50 0.15 0.13 –
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non-susceptible S. aureus following incubation with oritavancin (G.A.
McKay, S. Beaulieu, T.R. Parr Jr, G. Moeck, in Program and Abstracts of
the 48th Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy, Washington DC (2008) abstract no. C1-4182; [13]).
In the present work, and using calcein as a validated probe for the
study of lipid membrane permeabilization [21,23], and AFM to
investigate the effect of the lipoglycopeptide at the nanoscale, we
showed that oritavancin induced membrane permeabilization
together with changes in the lipid membrane organization in
domains. It is, however, important to remember that the two models
used, liposomes and supported lipid bilayers, are different, notably
regarding the curvature of the bilayer and the ability of the both
leaﬂets of lipids to be in contact with aqueous phases. The effects
induced by oritavancin are observed in the absence of any binding to a
D-Ala–D-Ala motif, indicating that alteration of membrane integrity is
probably not due to the aglycone part of the molecule, since its is
common to that of vancomycin, which exerts no effect in our models.
The mechanisms responsible for membrane permeabilization are
complex, but four main mechanisms have been proposed, namely (i)
the barrel-stave channel, i.e. a bundle of membrane-spanning helices
aligned with the polar side chains oriented towards the center [32,33]
(ii) the carpet-like mechanism where a monolayer of surface-lying
peptides covers the membrane surface [34], (iii) the toroidal model
[35,36], and (iv) the detergent-like peptidemodel [37]. Our study does
not provide direct evidence for either of thesemodels,which should be
the subject of future investigations. Especially the ability of oritavancin
to insert in the outer monolayer of the bilayer, leading to an
asymmetric increase in lateral pressure that tends to bend the bilayer
and induce a transient disruption of the membrane [37] has to be
examined. Moreover, the formation of rich clusters in the membrane
and destabilization of the lipid membrane by formation of mixed
micelles, could be determined.
If the permeabilization clearly depends on drug structure, the lipid
composition, and therefore the physical properties of membranes, can
also play a critical role for permeabilization. This is clearly reﬂected by
the ranking found for the ability of oritavancin to permeabilize lipid
bilayers (CL:POPENPOPC:POPENPOPG:POPENDPPG:POPE). Four
parameters could be critical in this respect.
First, one feature that distinguishes the membrane of prokaryotic
organisms from that of eukaryotic organisms is that only the former
harbor negatively-charged lipids in the outer leaﬂet of the plasma
membrane. So a large proportion of negatively-charged lipids,
especially POPG, is generally considered critical for the selectivity of
action of antibacterial peptides and lipopeptides [1]. Recently,
however, this point has been questioned. Some amphipathic α-helical
peptide analogues derived from Helicobacter pylori [38] had strong
antibacterial activity despite weak binding to phosphatidylglycerol.
Similarly, homologous antimicrobial oligomers mimicking host
defense peptides are not sensitive to charge [39]. Regarding
oritavancin, clearly, the presence of negatively-charged lipids is notthe only parameter required to induce the maximal membrane
permeabilization since a higher permeabilizing effect has been
observed on bilayers of POPC:POPE as compared to POPG:POPE. This
is in agreement with other studies performed on plantaricin A, a 26-
residue peptide pheromone, for which leakage of calcein from SOPC:
POPG vesicles is less extensive than from SOPC vesicles [40]. Similarly,
pardaxin, a membrane-lysing peptide originally isolated from the ﬁsh
Pardachirus marmoratus, also shows a lower ability to disrupt POPG:
POPE as compared to homogenous POPC bilayers [41].
Second, besides electrostatic interactions, the ability of phospho-
lipids to form H bonds could also be a major parameter governing
their interaction with glycopeptides. Indeed, POPG:POPE bilayers
show a high propensity to interact through hydrogen bonds with
phosphate and carbonyl oxygen atoms, as well as a much denser
packing of chain atoms in the near-the-interface regions of the
hydrophobic core, as compared to POPC bilayers [42]. Moreover, POPG
is less hydrated and shows a low probability of gauche conformation
in the beginning of the β-chain as compared to POPC [43]. This may
contribute to disturb packing of atoms in the near-the-interface
regions of the POPC bilayer core, creating defects and explaining why
oritavancin showed greater permeabilizing effect towards POPC:POPE
(4:8) than POPG:POPE (4:8).
Third, the propensity of CL and PE to induce negative curvature and
adopt hexagonal phase [44,45] may also contribute to favor the
permeabilization induced by oritavancin. At a molecular level, the
polar headgroup of PE is characterized by a smaller diameter than the
hydrocarbon chain region in the ﬂuid phase. This results in amolecular
shape of a truncated cone and an intrinsic propensity of PE bilayers to
form surfaces with a negative curvature, leading to the formation of
non-lamellar phases. Formation of hexagonal phase can be related to
high compressibility in ﬂuid phase [46], to an ability to easily adapt to
highly irregular surfaces [47], and to provide the lateral force for an
adequate stress proﬁle [46,48]. This could thus explain why, when the
POPE content is increased in liposomes containing POPC:POPE, an
enhancement of calcein release is observed. In CL:POPE liposomes, the
rapid and important effect of oritavancin on membrane permeability
could result from a local reduction in electrostatic repulsion between
cardiolipin molecules, thus imposing negative curvature strain on the
membrane. In comparison to CL:POPE, the lower permeabilizing effect
of oritavancin on POPG:POPE liposomes, could be related to the fact
that PG preferentially adopts a cylindrical molecular shape and forms
ﬂat bilayer, even at high temperatures.
Fourth, the unsaturated nature of the bacterial phospholipid
confers ﬂuidity to the membrane and possibly augments the insertion
of exogeneous compounds like antimicrobial peptides [49] or the
glycopeptides themselves [50]. The higher release of calcein from
liposomes of POPG:POPE: as compared to DPPG:POPE could result
from this.
AFM, a now well-established technique for imaging supported
lipid bilayers at nanometer resolution [14] has also provided us with
useful information on the changes brought by oritavancin on bilayer
Fig. 6. Nanoscale membrane activity of vancomycin (top) or oritavancin (bottom) on CL:POPE (2:8) supported bilayer. AFM height images (5 μm×5 μm; z-scale: 20 nm) of CL:POPE
supported planar bilayer recorded prior (0min) (A; C) or after exposure for 1 h to vancomycin (5.5 μM [8mg/L]) (B) or oritavancin (84 nM [0.15 mg/L]) (D). Vertical cross-sections were
takenalongtheposition indicatedby thecontinuous line.Upperdomainandmicaare indicatedbyblackandwhite stars, respectively.White arrows showeddomainsenriched incardiolipin.
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the air–water interface, and comparing the values of the excess energy
of mixing, showed that the composition chosen (CL:POPE at 2:8 molar
ratio) was the most stable [51]. In addition to the lateral phase
separation due to the differences in molecular structure, POPE and CL
can simultaneously undergo a thermal transition at the same time
[52], explaining the occurrence of the three domains in a binary
system observed by AFM. Since increasing the amount of cardiolipin
resulted in an increase of the area occupied by the upper domains, it
has been assumed that the lower domain is mainly formed by POPE
whereas the upper domain is mainly formed by cardiolipin [52].
We show here that oritavancin did not modify the height of a
supported bilayer of POPE, but decreased the step height between themica surface and the surface of the more extended domain in the CL:
POPE bilayer. In a supported bilayer of pure POPE, the PE headgroups
can form hydrogen bonds between adjacentmolecules [53] conferring
rigidity to the surface, while in a CL:POPE mixed supported bilayer,
cardiolipin molecules can disturb the formation of the hydrogen
bounds network [51]. Thus, oritavancin could interact with CL, which
tends to form non-lamellar phases, promoting a negative curvature in
the region of the domain and destroying its integrity (detergent-like
peptide model) [37].
Our studies were performed under conditions that are pertinent to
the antibacterial activity of oritavancin, in that we (i) used bilayers
that, like bacterial membranes, are rich in both a negatively-charged
lipid like phosphatidylglycerol and/or cardiolipin and phosphatidy-
1839O. Domenech et al. / Biochimica et Biophysica Acta 1788 (2009) 1832–1840lethanolamine [16,17,19,20]; (ii) performed all observations at con-
centrations of oritavancin that are similar to those at which
bactericidal effects can be demonstrated in vitro towards both
vancomycin-susceptible and vancomycin-resistant S. aureus or other
Gram-positive organisms [24,54,55]. These ranges of concentrations
are also those reached in serum during conventional administration of
the drug to humans [55]. All together, the data, therefore, strongly
suggest that membrane effects are responsible for the increased
potency of oritavancin as compared to vancomycin (and its activity
against vancomycin-resistant organisms). Moreover, recent studies
have demonstrated that oritavancin induced rapid bactericidal activity
against both exponential phase and stationary-phase inocula of S.
aureus in relation with membrane depolarization and membrane
permeabilization [13]. It remains, however, that membrane-destabi-
lizing effects of oritavancin, if critical for its antibacterial activity, must
be largely speciﬁc to prokaryotic cells since cellular experiments with
eukaryotic cells failed to markedly affect the cell viability (assessed by
measuring the release of a cytosolic enzyme, the lactate deshydro-
genase) of macrophages incubated with concentrations of up to
25 mg/L, i.e. 200-fold the minimal inhibitory concentration observed
in vitro for the least susceptible bacteria [25]. The explanation
probably lies in the difference in membrane composition and more
speciﬁcally, in the lack of signiﬁcant amounts of POPG or CL in the
pericellular membrane of eukaryotic cells.
An important aspect underlined by our studies is that only weak
alterations in membrane permeability or bilayer morphology were
seen with large concentrations of vancomycin. These cause killing of
Gram-positive organisms in vitro, but through a slow-acting mechan-
ism unrelated to direct membrane destabilization but, most likely, to
the activation of autolytic enzyme systems [56] through signal
transduction (via a death signal peptide) common to vancomycin
and β-lactams [57,58].
Other hypotheses, however, could be suggested. If oritavancin and
vancomycin are comparable inhibitors of transglycosylation, orita-
vancin is also a potent inhibitor of transpeptidation [59]. Moreover, in
addition to the binding to the primary site D-Ala–D-Ala, sequestration
of lipid II and inhibition of transglycosylation, the hydrophobic
biphenyl moiety and components of the aglycone structure of
oritavancin could form a secondary binding site for pentaglycyl
segments [59,60] due to the biphenyl group that contributes to an
enlargement of the drug hydrophobic surface area [61]. Also, the fact
that all effects can be seen at very low concentrations is of direct
importance. Indeed, oritavancin has been shown to dimerize easily,
and this, together with its membrane anchoring properties, has been
proposed as an important determinant in its superior activity to
vancomycin by favoring its interaction with the D-Ala–D-Ala motif
[62]. Dimerization is not only critical for peptide recognition but also
for membrane destabilization as it has been shown for antibacterials,
such as cathelicidin [63] or magainin [64]. Oligomerization could
enhance the kinetics and thermodynamic stabilities of the complex
formed [65] and affect the rate of association/dissociation to/from
lipids [66]. Lastly, a hydrophobic effect could also be important but
with some degree of speciﬁcity, as no beneﬁcial effect is observed
when an aliphatic chain was introduced to the E-ring of vancomycin
[67].
In conclusion, our work has advanced the characterization of the
interaction between oritavancin, a novel lipoglycopeptide endowed
with potent antimicrobial activity, and phospholipid bilayers. Our
observations indicate that lipid composition is a critical parameter
in this context with a clear role played by cardiolipin. This effect is
probably related to changes in the local physico-chemical properties
of the membranes, such as the surface charge, ability to form H
bonds, curvature, and ﬂuidity. Future biological and pharmaceutical
research may help in developing and expanding these observations
on what may constitute essential parts of antimicrobial armamen-
tarium in the future.Acknowledgements
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